Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in Subjects With Unexplained or Refractory Chronic Cough (RELIEF)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 20 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 May 2023 Results from NCT03638180 , NCT03979638 and NCT04678206 evaluating the model-informed dose selection for phase 3 trials, presented at the 119th International Conference of the American Thoracic Society.
10 Nov 2021 According to a BELLUS Health media release, data from the study was presented at the European Respiratory Society International Congress 2021.
01 Nov 2021 According to a BELLUS Health media release, clinical evidence from this trial will be reviewed at the live webcast to be held on November 15, 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com